
ããã¯ã¯ãã³ãå«ããã¹ãŠã®mRNA泚å°ã¯ãããã®çºçãä¿é²ããå¯èœæ§ãããã
å èšäºã¯ãã¡ããã/Click here to read the original article.
4æ¥åããã¬ãŒãã£ã¢ã³ãçŽã¯ãããã«å¯Ÿãã "åå¥åmRNAã¯ã¯ãã³ "ã第3çžèšåºè©Šéšã«å
¥ããè±åœã§ã¯ "æ£è
ãç ç©¶è
ã®éã§è奮ãåºãã£ãŠãã "ãšå ±ãããæææ¥ã«ã¯ããã€ã³ã»ãŠã¢ã»ãšãªã¢ãçŽããèºãããèè±ãããè
èããã«ãæå¹ãããããªãåå¥åmRNAç®èããã¯ã¯ãã³ã«é¢ããèšäºãæ²èŒããã
ããããå
é±çºè¡šãããè«æãèªããšãæ£è
ã¯ãã® "ç»æç㪠"泚å°ã«ããŸãè奮ããªããããããªãã
4æ23æ¥ãåŠè¡èªãAuthoreaãã«ãmRNA泚å°ã«ããçºçãšèªå·±å
ç«ã«ã€ããŠæ€èšãããã¬ããªã³ãè«æïŒæ»èªã¯ãŸã ïŒãæ²èŒãããã ããã«ãããšãmRNA泚å°ãç¹°ãè¿ããšãããã«å¯Ÿããå
ç«ç£èŠæ©èœãäœäžããåæã«èªå·±å
ç«ãèªå°ãããããšãããã£ãã
ããã«èªã
çºãããšã¯ãå¥åº·ãªçްèããã现èãžãšå€åããéçšãæãã
èªå·±å ç«ãšã¯ãå ç«ç³»ãèªåèªèº«ã®çްèãçµç¹ã "èªå·± "ãšããŠèªèã§ããªãããã«èµ·ããå ç«åå¿ã§ããã
ãã®è«æã§ã¯ãå ç«ç³»ã«ãããå¶åŸ¡æ§T现èïŒãTregãïŒã®åœ¹å²ã«ã€ããŠãç¹ã«mRNA泚å°ã«ãã£ãŠåŒãèµ·ããããTreg现èã®è¡åé害ã«çŠç¹ãåœãŠãå¹ åºãã¬ãã¥ãŒããŠããã
Treg现èã¯å ç«ç³»ã調ç¯ããèªå·±æåã«å¯Ÿããå¯å®¹ãç¶æããèªå·±å ç«çŸæ£ãäºé²ããããŸããTreg现èã¯çã«å¯Ÿããå ç«åå¿ãæå¶ããçã®çºçãšé²è¡ã«å¯äžããããšã瀺ãããŠããã
ãã®è«æã§ã¯ãã¯ã¯ãã³æ¥çš®åŸããã®åŸã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çºçŸãããã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ã«æå®³ãªåœ±é¿ãåãŒãããã®åŸããããèªå·±å ç«çŸæ£ã®çºçãå éãããå¯èœæ§ããã ããšããã
ãã®è«æã§ã¯ãã³ããmRNA泚å°ã«é¢é£ãããããã®ç¶æ³ãç¹ã«ã¬ãã¥ãŒããŠããããè«æã§æèµ·ãããæžå¿µã¯ãã¹ãŠã®mRNA泚å°ã«åœãŠã¯ãŸãã
ãæ²ããããšã«ãå€ãã®mRNAäŒæ¥ã®äžã§ã¢ããã¯mRNAçæ²»çè¬ãèšç»ããŠããã圌ãã¯ãmRNAãæ²»çç®ç以äžã®çãåŒãèµ·ãããªãããšã蚌æããããã«ãé·ãè¬å€éçºçµè·¯ãæã£ãŠããŸãããšããŒã¿ãŒã»ããã«ããŒå士ã¯èšãã
mRNAã³ãŽã£ã-19ã¯ã¯ãã³æ¥çš®ã®çµæãšããŠã®çºçãšèªå·±å ç«
ããŒã¿ãŒã»ããã«ããŒå士è
äžçäžã®ããããããç»é²ãæ°èŠçäŸã§å¢å ãã"ã¿ãŒããã "ãšåŒã°ããçŸæ£ã®æ¥éãªé²è¡ãèšé²ãããŠããããã¬ã³ãã©ã€ã³ã¯éºäŒåã³ãã-19ã¯ã¯ãã³ã®å±éãšãšãã«äžæããããã¡ã€ã¶ãŒç€Ÿãã¢ãã瀟ã®mRNAã®æ³šå ¥ãšçã®çºçã説æã§ããã¡ã«ããºã ã¯äœã ãããïŒ
ããªã¢ã³ããã¹ïŒKyriakopoulosïŒãã¯æè¿ã倿¥mRNAãç¹°ãè¿ã泚å°ããåŸã®å¶åŸ¡æ§T现èã«ããåå¿ã«ã€ããŠåŸ¹åºçãªèª¿æ»ãè¡ã£ãã
T-ãšãã§ã¯ã¿ãŒçްèãT-ã¬ã®ã¥ã©ããªãŒçްèãã¡ã¢ãªãŒT-ã¬ã®ã¥ã©ããªãŒçްèã®éã®ãã¡ãªã¹ã¿ã·ã¹ãã©ã³ã¹ãäžé©åã§ãããšãå ç«ç³»ãããåãŸãã¯èªå·±å ç«ã®ããããã«åããããå¯èœæ§ãããããããååšããå ŽåãTreg现èã¯æè «çå ç«ãæå¶ãããããååšããªãå ŽåãTreg现èã¯èªå·±å ç«ã®çºçãé²ããšããæçãªåœ¹å²ãæããã
ãã®ç·èª¬ã§ã¯ãSARS-CoV-2 mRNAã¯ã¯ãã³æ¥çš®åŸã®Tregå¿çãè§£æããç°ãªãæ¡ä»¶äžã§ã®æç¢ºãªç çåŠçå¿çãèŠåºãããããæ£è ã§ã¯ãã¯ã¯ãã³æ¥çš®æã®ããã®ç¶æ ããåæã«åããããæ²»çã®çš®é¡ã«ãã£ãŠãç ç¶ã®é²è¡ã®çšåºŠãç°ãªããæã ã¯ãåŸªç°æš¹ç¶çްèãšmTreg现èã®èžè ºãžã®ç§»åããå ç«èåã®çŽæ¥çãªåå ã§ããèžè ºã®éçž®ãä¿é²ãããšãã仮説ãç«ãŠãã
ãŸãšãããšãmRNAã¯ã¯ãã³æ¥çš®åŸã«ç£çãããTregå¿çãšãããã«ç¶ãmRNAã³ãŒãåSARS-CoV-2ã¹ãã€ã¯ã¿ã³ãã¯çºçŸã¯ãã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ã«æå®³ãªåœ±é¿ãåãŒãããã®çµæããããèªå·±å ç«çŸæ£ã®çºçãå éãããå¯èœæ§ãããããããã®ã¡ã«ããºã ã¯ãç«åŠçç¥èŠãçäŸå ±åãšãäžèŽããŠããã
èšãæããã°ãmRNAã³ãã-19ã¯ã¯ãã³ã®å埩泚å°ã¯ãæ°çæªæ§çްèã«å¯Ÿããå ç«ç£èŠæ©èœã忢ããããšåæã«ãèªå·±å ç«ãèªå°ããŠããã®ã§ããã

åèšåºããåæ§è©Šéšãã¹ãããããããšã¯ãmRNA補åã«ãšã£ãŠçœé£ã§ããããšã倿ããããã®è«æã§æèµ·ãããæžå¿µã¯ããã以å€ã®ããããã¯ç çåŠçãªã¿ã³ãã¯è³ªæšçãã³ãŒãããæ°ããmRNA補åã«ãåœãŠã¯ãŸããæ²ããããšã«ãå€ãã®mRNAäŒæ¥ã®äžã§ãã¢ããã¯ãmRNAããæ²»çè¬ã®èšç»ãæã£ãŠããã圌ãã¯ãmRNAãæ²»çç®ç以äžã®çãåŒãèµ·ãããªãããšã蚌æããããã«ãé·ãè¬å€éçºçµè·¯ãæã£ãŠããã